Catalyst Pharmaceuticals (CPRX) Given Media Impact Rating of 0.10

Headlines about Catalyst Pharmaceuticals (NASDAQ:CPRX) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.5130842277274 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s analysis:

How to Become a New Pot Stock Millionaire

NASDAQ CPRX traded up $0.07 during trading on Wednesday, reaching $2.61. The company’s stock had a trading volume of 166,818 shares, compared to its average volume of 654,786. The company has a market capitalization of $261.52, a P/E ratio of -12.52 and a beta of 1.62. Catalyst Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $4.51.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.06). research analysts forecast that Catalyst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Several analysts recently commented on CPRX shares. BidaskClub downgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 24th. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, December 21st. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $6.25.

In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany acquired 20,000 shares of the business’s stock in a transaction on Tuesday, April 3rd. The stock was purchased at an average price of $2.29 per share, with a total value of $45,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 9.60% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/18/catalyst-pharmaceuticals-cprx-given-media-impact-rating-of-0-10.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply